Edition:
United Kingdom

Novocure Ltd (NVCR.OQ)

NVCR.OQ on NASDAQ Stock Exchange Global Select Market

20.00USD
4:12pm GMT
Change (% chg)

$0.05 (+0.25%)
Prev Close
$19.95
Open
$19.95
Day's High
$20.25
Day's Low
$19.90
Volume
135,775
Avg. Vol
221,317
52-wk High
$22.25
52-wk Low
$6.00

Chart for

About

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM)... (more)

Overall

Beta: --
Market Cap(Mil.): $1,606.50
Shares Outstanding(Mil.): 89.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Novocure Receives Reimbursement Approval For Optune In Japan For Treatment Of Glioblastoma

* NOVOCURE RECEIVES REIMBURSEMENT APPROVAL FOR OPTUNE® IN JAPAN FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

01 Dec 2017

BRIEF-Novocure reports qtrly ‍loss per share $0.13​

* Novocure Ltd - ‍Q3 2017 net revenues of $50.1 million, reflecting 131 percent growth versus Q3 2016​ Source text for Eikon: Further company coverage:

26 Oct 2017

BRIEF-Novocure qtrly net revenues $38.4 mln

* Novocure Ltd - ‍for three months ended June 30, 2017, net revenues increased to $38.4 million compared to $17.9 million for same period in 2016​

27 Jul 2017

BRIEF-Novocure to initiate early-stage trial testing its glioblastoma combo therapy

* Novocure™ announces a phase 1b clinical trial to evaluate the safety of marizomib and temozolomide in combination with optune® as adjuvant therapy in patients with glioblastoma

24 Jul 2017

Earnings vs. Estimates